ProCE Banner Activity


Targeting BTK in CLL: Expert Guidance on Selecting Single-Agent and Combination Therapy

Watch this on-demand webcast of a live CCO webinar where global experts discuss the latest advances in the use of BTK inhibitors in managing patients with CLL.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: December 10, 2021

Expiration: December 09, 2022

No longer available for credit.



Seema Ali Bhat

Seema Ali Bhat, MD

Associate Professor
Division of Hematology
Department of Medicine
The Ohio State University
Columbus, Ohio

Talha Munir

Talha Munir, MBBS, MRCP, FRCPath

Consultant Haematologist
Department of Haematology
St Jamess Hospital
Leeds, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by an educational grant from


Target Audience

This program is intended for global hematologists, oncologists, and other healthcare professionals involved in the management of patients using BTK inhibitors in the treatment of patients with CLL.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss with patients differences between first- and next-generation BTK inhibitors in terms of molecular characteristics, selectivity, preclinical data, approved indications, dosing, safety profile, and efficacy
  • Plan optimal BTK inhibitor–based therapy for patients with CLL, taking into consideration guidelines, expert recommendation, and recent practice-changing clinical trial results
  • Recognize and manage adverse events and toxicities associated with BTK inhibitor therapy to support adherence, appropriate dosing, quality of life, and continuation of treatment
  • Evaluate ongoing clinical trials investigating available and emerging BTK inhibitors as single agents and in combination


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Seema Ali Bhat, MD

Associate Professor
Division of Hematology
Department of Medicine
The Ohio State University
Columbus, Ohio

Seema Bhat, MD, has disclosed that she has received funds for research support from Acerta, AstraZeneca, and TG Therapeutics, and consulting fees from Acerta, AstraZeneca, and BeiGene.

Talha Munir, MBBS, MRCP, FRCPath

Consultant Haematologist
Department of Haematology
St Jamess Hospital
Leeds, United Kingdom

Talha Munir, MBBS, MRCP, FRCPath, has disclosed that he has received consulting fees from Alexion, AstraZeneca, Janssen and Roche; and fees for non-CME/CE Services from Alexion, AbbVie, AstraZeneca, and Janssen.

Staff Disclosure


Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD has no relevant conflicts of interest to report.

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.

Instructions for Credit


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 10, 2021, through December 09, 2022:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize the use of current and emerging therapeutic strategies with BTK inhibitors in the care of their patients with chronic lymphocytic leukemia.